Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs Medical Health Institute

FuturHealth
Graded #215

Higher grade

vs+12.299999999999997
Medical Health Institute
Graded #469

Lower grade

The verdict

FuturHealth takes it — 65.6/100 to 53.3/100.

FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFuturHealth +15
60
45
Dose & formulationFuturHealth +41
81
40
Clinical oversightMedical Health Institute +2
67
69
Labs & monitoringFuturHealth +9
61
52
FulfillmentMedical Health Institute +5
62
67
Contract termsEven
55
55
FuturHealth · left barMedical Health Institute · right bar

The numbers

MetricFuturHealthMedical Health Institute
WeighScore65.6/10053.3/100
GradeCC
Scorecard rank#215#469
Semaglutide$199/mo (compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Medical Health Institute

Graded #469 · C

Strengths

  • Operating entity disclosed: Medical Health Institute, LLC, with full Pinecrest, FL address and phone
  • Named medical director (Amy Wecker, MD) plus four more named clinicians on the about page
  • Three care pathways with starting-price anchors: $99 TRT / $129 peptides / $149 weight-loss
  • LegitScript Certified with a footer verification link
  • HIPAA compliance claimed

Where it loses points

  • GLP-1 medication options (semaglutide vs tirzepatide; compounded vs brand) not shown — gated behind the intake funnel
  • Pharmacy partner not named — only generic 'FDA-regulated facilities' language
  • State availability not disclosed
  • Several subpages (/weight-loss, /pricing, /products, /faq) returned server errors during verification
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard